Our previous studies confirmed that the combined infusion of humanized anti-CD19 and anti-BCMA CAR-T cells is feasible and that the majority of patients with R/R MM achieved high response rates (19, 20). The gene discussed is CD19; the disease is Miyoshi myopathy.